1.35
-6.90%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CEL-SCI
From its filings with the US Securities and Exchange Commission
CEL-SCI is based in Vienna, Virginia and is incorporated in Colorado. Its shares trade on NYSE under the ticker CVM. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 September 2014, it reported revenue of $264,033.
L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.
Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review under CEL-SCI’s future anticipated regulatory submission for approval. None of CEL-SCI’s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.
The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth.
Quoted from its 10-K, filed 29 Dec 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Dec 1983
- Employees
- 43
- Website
- cel-sci.com ↗
- Head office
- 8229 BOONE BLVD ., VIENNA, VA, 22182
- Incorporated in
- CO
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Robert WatsonIndependent Chairman of the Board$147,990
- Mr. Geert KerstenChief Executive Officer, Chief Financial Officer, Treasurer, Director, since 1995$1.1m
- Ms. Patricia PrichepCo-Chief Financial Officer, Chief Operating Officer, Corporate Secretary$542,744
- Mr. John CiprianoSenior Vice President - Regulatory Affairs$249,593
- Dr. Daniel ZimmermanSenior Vice President - Research, Cellular Immunology$46,077
- Dr. Eyal TalorChief Scientific Officer$613,023
- Mr. Bruno BaillavoineIndependent Director$142,131
- Mr. Mario GobboIndependent Director$111,760
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 47
- Social
- 40
- Governance
- 42
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CEL-SCI's Multikine targets head and neck cancers with 43 employees focusing on immunotherapy development.
- L.E.A.P.S. technology supports multiple therapies including LEAPS-H1N1-DC for pandemic influenza treatment.
- Research segment develops vaccines for rheumatoid arthritis with CEL-2000 and CEL-4000 candidates.
Weaknesses
- Limited workforce of 43 employees may hinder rapid development of multiple therapies.
- Vienna, Virginia headquarters lacks major biotech infrastructure for scaling operations.
- No established commercial products yet, relying solely on investigational therapies.
Opportunities
- Growing demand for immunotherapy treatments in head and neck cancer markets.
- Potential for L.E.A.P.S. technology to expand into new infectious disease applications.
- Rheumatoid arthritis vaccine candidates CEL-2000 and CEL-4000 could address large patient segments.
Threats
- Competition from established biotech firms in immunotherapy and vaccine development.
- Regulatory hurdles for investigational therapies like Multikine and LEAPS-H1N1-DC.
- Financial constraints due to reliance on research funding without commercial revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.